Utah Retirement Systems’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.09M Sell
20,236
-365
-2% -$110K 0.06% 284
2026
Q1
$6.82M Sell
20,601
-124
-0.6% -$42.2K 0.07% 259
2025
Q4
$8.24M Buy
20,725
+126
+0.6% +$55.8K 0.08% 225
2025
Q3
$9.39M Sell
20,599
-371
-2% -$151K 0.09% 202
2025
Q2
$6.84M Sell
20,970
-355
-2% -$98.2K 0.07% 261
2025
Q1
$5.76M Hold
21,325
0.07% 272
2024
Q4
$5.02M Buy
21,325
+400
+2% +$105K 0.06% 320
2024
Q3
$5.76M Buy
20,925
+200
+1% +$52.1K 0.06% 285
2024
Q2
$5.04M Sell
20,725
-800
-4% -$126K 0.06% 295
2024
Q1
$3.22M Buy
21,525
+100
+0.5% +$16.7K 0.04% 422
2023
Q4
$4.1M Buy
21,425
+100
+0.5% +$17K 0.05% 345
2023
Q3
$3.78M Buy
21,325
+100
+0.5% +$19.1K 0.05% 342
2023
Q2
$4.03M Sell
21,225
-600
-3% -$119K 0.06% 345
2023
Q1
$4.37M Buy
21,825
+54
+0.2% +$11.4K 0.06% 325
2022
Q4
$5.17M Buy
21,771
+199
+0.9% +$42.4K 0.08% 258
2022
Q3
$4.32M Buy
21,572
+200
+0.9% +$38.1K 0.07% 279
2022
Q2
$3.12M Hold
21,372
0.05% 361
2022
Q1
$3.49M Sell
21,372
-100
-0.5% -$15.2K 0.05% 382
2021
Q4
$3.64M Hold
21,472
0.05% 396
2021
Q3
$4.05M Sell
21,472
-800
-4% -$150K 0.05% 345
2021
Q2
$3.77M Buy
22,272
+100
+0.5% +$14.6K 0.05% 388
2021
Q1
$3.13M Sell
22,172
-1,000
-4% -$150K 0.04% 415
2020
Q4
$3.01M Buy
23,172
+1,000
+5% +$134K 0.04% 413
2020
Q3
$3.23M Buy
22,172
+400
+2% +$56.8K 0.05% 335
2020
Q2
$3.23M Buy
21,772
+1,600
+8% +$216K 0.06% 311
2020
Q1
$2.2M Hold
20,172
0.05% 361
2019
Q4
$2.32M Buy
20,172
+100
+0.5% +$9.97K 0.04% 433
2019
Q3
$1.61M Buy
20,072
+500
+3% +$39.6K 0.03% 545
2019
Q2
$1.42M Buy
19,572
+1,759
+10% +$135K 0.03% 599
2019
Q1
$1.67M Buy
17,813
+1,113
+7% +$93.1K 0.03% 516
2018
Q4
$1.22M Buy
16,700
+100
+0.6% +$7.69K 0.03% 568
2018
Q3
$1.45M Buy
16,600
+100
+0.6% +$10.1K 0.03% 584
2018
Q2
$1.63M Buy
16,500
+300
+2% +$29.8K 0.03% 525
2018
Q1
$1.93M Buy
16,200
+200
+1% +$25.8K 0.04% 451
2017
Q4
$2.03M Buy
16,000
+1,400
+10% +$176K 0.04% 438
2017
Q3
$1.72M Buy
14,600
+800
+6% +$68.3K 0.04% 469
2017
Q2
$1.1M Buy
13,800
+200
+1% +$12.8K 0.03% 628
2017
Q1
$697K Hold
13,600
0.02% 781
2016
Q4
$510K Sell
13,600
-100
-0.7% -$4.19K 0.01% 864
2016
Q3
$928K Hold
13,700
0.02% 654
2016
Q2
$760K Buy
13,700
+400
+3% +$25.2K 0.02% 720
2016
Q1
$835K Hold
13,300
0.02% 678
2015
Q4
$1.25M Hold
13,300
0.03% 525
2015
Q3
$1.07M Buy
13,300
+100
+0.8% +$11.1K 0.03% 579
2015
Q2
$1.58M Buy
13,200
+300
+2% +$35.9K 0.04% 461
2015
Q1
$1.35M Buy
12,900
+1,400
+12% +$142K 0.04% 536
2014
Q4
$1.11M Hold
11,500
0.03% 570
2014
Q3
$898K Hold
11,500
0.03% 635
2014
Q2
$726K Buy
+11,500
New +$684K 0.02% 765

Other funds holding ALNY

Utah Retirement Systems's ALNY Position: Q2 2026 in Review

Utah Retirement Systems reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.8% in Q2 2026, selling an estimated $110K and leaving 20,236 shares worth $6.09M. The position accounts for 0.06% of the portfolio, ranked #284.

Utah Retirement Systems first reported a position in ALNY in Q2 2014 and has held it in 49 quarters since. The position peaked at $9.39M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Utah Retirement Systems held 20,236 shares of Alnylam Pharmaceuticals worth $6.09M as of Q2 2026.
  • Utah Retirement Systems sold 365 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $110K.
  • Alnylam Pharmaceuticals made up 0.06% of Utah Retirement Systems's portfolio in Q2 2026, its #284 holding.
  • Utah Retirement Systems first reported a position in Alnylam Pharmaceuticals in Q2 2014 and has held it in 49 quarters since.
  • Utah Retirement Systems's Alnylam Pharmaceuticals position peaked at $9.39M in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Utah Retirement Systems's 13F filing for Q2 2026, filed 14 Aug 2026.